NeuroBasic-PharmaPhenomics


At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: Netherlands
  • Initiator Type: Government
  • Disease focus:
    Neurological and psychiatric disease
  • Location: Europe

Abstract

NeuroBasic-PharmaPhenomics wants to build new rodent models of neurological and psychiatric diseases and translate preclinical studies of animal models into novel treatments for human patients.

Mission

NeuroBasic is part of the Drugs cluster. The Drugs cluster offers the platform for the integrated approach necessary for the development of effective and safe new drugs to increase health. These activities are carried out with a simultaneous focus on economic benefits to ensure wealth for the Dutch economy: jobs, (foreign) investments, and increased entrepreneurial activity.

The Drugs cluster will deliver partnership, patents, publications, and projects moving into clinical development. In addition the Drugs cluster will create a new generation of research professionals and further international expansion. The Drugs cluster builds on the strong take off of TI Pharma and consolidates and aligns scattered initiatives, including selective continuity for research in three successful BSIK consortia: Neuro-BSIK, Virgo, and CDC. The chosen research lines were selected on excellence and their fit with the Drugs cluster focus (guided by the World Health Organization’s Priority Medicines report).

The Drugs cluster consists of four research lines and three strategic actions for the project portfolio development of TI Pharma:

  • NeuroBasic-PharmaPhenomics (line 1): Developing drug discovery strategies in the field of neurology

  • NeuroBasic-PharmaPhenomics (line 2): Developing drug discovery strategies in the field of psychiatry

  • Viral infections: Discovering new viruses, building on knowledge of molecular prognostic, diagnostic, and therapeutic markers in viral infections and unraveling the underlying mechanisms of mutual host-virus interactions, with the overall purpose of developing better (more timely and effective) interventions for acute and chronic viral infections

The NeuroBasic project builds on the achievements of the NeuroBSIK-MousePhenomics consortium.

Consortium History

March 2011: Kickoff meeting held

Structure & Governance

Apart from the overall managerial Work Packages (WPs) to warrant the interactions among the WPs (WP0; WP leader Chris De Zeeuw), each of the two main research lines is divided into nine WPs that run in parallel. Each covers the various phases in the timelines and each as a designated WP leader.

Points of Contact

Annemieke Steenbergen
Project Manager
PO Box 71033
1008 BA Amsterdam
The Netherlands
phone: +31 (0)20 598 35 55
mobile: +31 (0)6 42 26 55 14
email: annemieke.steenbergen@sylics.com
website: www.sylics.com

Sponsors & Partners

Delta Phenomics BV

Erasmus MC Rotterdam

Griffin Discoveries BV

Ministry of VWS

Neurasmus BV

Noldus Information Technology BV

Psynova Neurotech LTD

Sylics

UMC Utrecht

VU Amsterdam

VU University Amsterdam

Wageningen University & Research Centre


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.